Amgen Inc. (AMGN)
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
Amgen (AMGN) closed at $325.09 in the latest trading session, marking a +0.14% move from the prior day.
Calls of the Day: Amgen, Albemarle, Tesla, Broadcom and Caterpillar
The Investment Committee discuss the latest Calls Of The Day.
Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.
The pharma company has a lot riding on its experimental obesity drug MariTide.
Amgen's stock falls as analyst warns that hype around obesity drug is baked in
Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech's drug pipeline.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
Income stocks can be wise additions to your portfolio in any market environment.
2 Biotech Stocks to Buy Hand Over Fist in October
These longtime leading biotech stocks still have plenty of upside ahead.
The Art of Valuation: Discovering Amgen Inc's Intrinsic Value
In this article, we will take a look into Amgen Inc's (AMGN, Financial) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as in the traditional DCF model, the GuruFocus DCF calculator uses EPS without NRI as the default for the DCF model based on research that shows that historically stock prices have been more correlated with earnings than free cash flow.
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Investing in the most popular players in the space isn't the only valid approach.
Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know
Amgen (AMGN) concluded the recent trading session at $319.66, signifying a +0.69% move from its prior day's close.
Alumis: Could This Broken Immunology IPO Become The Next Amgen?
With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? Investors who buy now can get it around 30% under the June 28th IPO price. Alumis is backed by prominent healthcare hedge funds such as Baker Brothers, VenBio, and Cormorant Asset Management.
